ProQR Therapeutics announced that its sepofarsen drug candidate, also known as QR-110, has received access to a program for promising medicines, according to a press release.
Sepofarsen was granted access into the European Medicines Agency’s Priority Medicines (PRIME) program, which offers a pathway of accelerated evaluation and approval for medicines that may provide a therapeutic advantage over existing treatments or that are for indications that currently have no treatment options, according to the release. Sepofarsen is under development as a treatment for Leber’s congenital
Uncategorized